| Chemical Properties | Back Directory | [Boiling point ]
739.1±70.0 °C(Predicted) | [density ]
1.28±0.1 g/cm3(Predicted) | [solubility ]
DMSO:30.0(Max Conc. mg/mL);47.56(Max Conc. mM) | [form ]
Solid | [pka]
11.10±0.40(Predicted) | [color ]
White to off-white | [InChIKey]
FRVSRBKUQZKTOW-YOCNBXQISA-N | [SMILES]
C(N(CC)C(C)C)(=O)C1=CC(F)=CC=C1OC1=CN=CN=C1N1CC2(CCN(C[C@@H]3CC[C@@H](NS(CC)(=O)=O)CC3)CC2)C1 |
| Hazard Information | Back Directory | [Uses]
Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)[1]. | [in vivo]
Revumenib (SNDX-5613) shows in vivo plasma IC50 of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts[1]. | [References]
[1] A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory). |
|
|